Edwards Lifesciences Corporation (EW) reported adjusted earnings per share (EPS) of 66 cents in first-quarter 2024, surpassing the Zacks Consensus Estimate by 3.1%. The figure also increased 6.5% from the year-ago quarter’s level.The quarter’s one-time adjustments primarily include certain litigation expenses and amortization of intangible assets, among others.GAAP EPS were 58 cents in the quarter, up 3.6% year over year.Sales DetailsFirst-quarter net sales were $1.59 billion, up 9.5% year over year on a re ...

Edwards Lifesciences Corporation (NYSE:EW) Q1 2024 Earnings Conference Call April 25, 2024 5:00 PM ET Company Participants Mark Wilterding - SVP & IR Bernard Zovighian - CEO Scott Ullem - CFO Daveen Chopra - Global Leader of TMTT Larry Wood - Group President of TAVR and Surgical Structural Heart Katie Szyman - Global Leader of Critical Care Conference Call Participants Robbie Marcus - JPMorgan Travis Steed - Bank of America Larry Biegelsen - Wells Fargo Matt Taylor - Jefferies Joanne Wuensch - Citi Matt Mik ...

Edwards Lifesciences (EW) reported $1.6 billion in revenue for the quarter ended March 2024, representing a year-over-year increase of 9.5%. EPS of $0.66 for the same period compares to $0.62 a year ago.The reported revenue represents a surprise of +1.43% over the Zacks Consensus Estimate of $1.58 billion. With the consensus EPS estimate being $0.64, the EPS surprise was +3.13%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determ ...

Edwards Lifesciences (EW) came out with quarterly earnings of $0.66 per share, beating the Zacks Consensus Estimate of $0.64 per share. This compares to earnings of $0.62 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 3.13%. A quarter ago, it was expected that this medical device maker would post earnings of $0.64 per share when it actually produced earnings of $0.64, delivering no surprise.Over the last four quarters, the co ...

Edwards Lifesciences Corporation One Edwards Way · Irvine, CA USA · 92614 Phone: 949.250.2500 · www.edwards.com FOR IMMEDIATE RELEASE Media Contact: Amy Hytowitz, 949-250-4009 Investor Contact: Mark Wilterding, 949-250-6826 • Q1 sales grew 10% on a reported and constant currency basis to $1.6 billion 1 • Q1 TAVR sales grew 6%; constant currency sales grew 8% adjusted for billing days • Q1 TMTT sales grew 75% • Q1 EPS of $0.58; adjusted EPS of $0.66 1 • Raising 2024 sales guidance to the high end of previous ...

The earnings season is in full swing now with several MedTech bigwigs already releasing first-quarter results. Per the latest Earnings Preview, quarterly results of the Medical sector have declined year over year, affected by the ongoing macroeconomic headwinds, primarily in the form of worldwide geopolitical issues and healthcare labor shortages.Going by the broader Medical sector’s scorecard, 5% of the companies in the Medical sector, constituting 19.4% of the sector’s market capitalization, reported earn ...

The upcoming report from Edwards Lifesciences (EW) is expected to reveal quarterly earnings of $0.64 per share, indicating an increase of 3.2% compared to the year-ago period. Analysts forecast revenues of $1.58 billion, representing an increase of 8% year over year.The consensus EPS estimate for the quarter has been revised 0.1% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.Pri ...

Edwards Lifesciences Corporation (EW) is scheduled to report first-quarter 2024 results on Apr 25, after market close.In the last reported quarter, the company’s adjusted earnings per share of 64 cents matched the Zacks Consensus Estimate. The company’s earnings beat estimates in two of the trailing four quarters and matched estimates in the other two. EW has a trailing four-quarter earnings surprise of 0.80% on average.Let's see how things have shaped up before this announcement.Factors at PlaySimilar to t ...

Edwards Lifesciences Corporation (EW) shares have surged 21.8% year to date compared with the industry’s rise of 7.2%. The Medical sector has gained 5.2% in the said time frame. The company has a market capitalization of $55.83 billion.The company’s consistent growth performance reflects its commitment to advancing its leadership in surgical structural heart therapies. The strategic spin-off of Critical Care aims to boost the company’s R&D and innovations and enable a sharpened focus on structural heart dis ...

PITTSBURGH--(BUSINESS WIRE)--PECA Labs, a medical device company reimagining the field of vascular grafts and valves with durable polymeric cardiovascular devices designed to fit, grow, and last, has received an additional CE Mark for its exGraft family of vascular grafts, expanding its on-label use. exGraft vascular grafts are intended for use as vascular prostheses for replacement or bypass of diseased or injured vessels, and with the new clearance, exGraft now includes instructions for post-operative exp ...